- Home
- CYBN
CYBN
Cybin Inc.
as 08-22-2025 4:00pm EST
Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The Company is a clinical-stage neuropsychiatric company focused on advancing therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions. The Company is developing technologies and delivery systems aimed at improving the pharmacokinetics of its proprietary molecules while retaining the therapeutic benefit. These new molecules and delivery systems are expected to be studied through clinical trials to confirm safety and efficacy.
| Founded: | 2019 | Country: | Canada |
| Employees: | N/A | City: | N/A |
| Market Cap: | 176.0M | IPO Year: | N/A |
| Target Price: | $85.00 | AVG Volume (30 days): | 332.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.65 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.81 - $13.88 | Next Earning Date: | 08-13-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Cybin Inc. News
CYBN Breaking Stock News: Dive into CYBN Ticker-Specific Updates for Smart Investing
Business Wire
a month ago
Cybin Receives UK MHRA Approval to Commence EMBRACE, A Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder
Insider Monkey
2 months ago
Cybin Granted Key Patent for CYB004 DMT Program, Supports GAD Treatment Development
TipRanks
2 months ago
Trump Trade: President said to weigh possible U.S. strike against Iran
TipRanks
2 months ago
Psychedelic advocates hopeful Trump administration will support space, STAT says
Newsfile
2 months ago
Psyence BioMed Chief of Global Impact to Speak at Psychedelic Science 2025
Business Wire
2 months ago
Cybin Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics
Business Wire
2 months ago
Cybin to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Conference
Business Wire
2 months ago
Cybin to Participate in the 2025 Psychedelic Science Conference
Compare CYBN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CYBN Cybin Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.